Treatment Patterns and Outcomes of Patients with Advanced Malignant Pleural Mesothelioma in a Community Practice Setting | Zendy

David Waterhouse | Zendy; Esmond Nwokeji | Zendy; Marley Boyd | Zendy; John R. Penrod | Zendy; Janet L. Espirito | Zendy; Nicholas J. Robert | Zendy; M. Daumont | Zendy

Open Access

Treatment Patterns and Outcomes of Patients with Advanced Malignant Pleural Mesothelioma in a Community Practice Setting

Author(s) -

David Waterhouse,

Esmond Nwokeji,

Marley Boyd,

John R. Penrod,

Janet L. Espirito,

Nicholas J. Robert,

M. Daumont

Publication year - 2021

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2021-0047

Subject(s) - pemetrexed , medicine , carboplatin , mesothelioma , oncology , nivolumab , regimen , gemcitabine , cisplatin , ipilimumab , chemotherapy , cancer , immunotherapy , pathology

Aim: To assess real-world treatment patterns and outcomes among patients with advanced malignant pleural mesothelioma. Patients & methods: Retrospective database analysis. Results: In all, 469 patients received first-line systemic anticancer therapy (SACT) at community centers. Median follow-up from diagnosis was 11.6 months. Pemetrexed + platinum was the most common first-line SACT; similar proportions of patients received cisplatin or carboplatin with pemetrexed. Only a small proportion of patients received second- and third-line therapies. Median overall survival for first-line SACT was 12.0 months (95% CI: 10.7–14.2). Results were similar with pemetrexed + cisplatin and pemetrexed + carboplatin. Median overall survival with second-line SACT was 6.4 months (95% CI: 5.1–7.6). Conclusion: There is a need for more effective SACTs for advanced malignant pleural mesothelioma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research